{
  "abstract": "Introduction: Anti-CD38-based quadruplets such as daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd) or daratumumab-bortezomib-thalidomide-dexamethasone (D-VTd), where lenalidomide is not reimbursed, are the internationally recommended first-line treatment for transplant-eligible myeloma. There is ongoing debate about whether anti-CD38 exposure impairs stem cell collection. Most studies compare daratumumab-containing with non-daratumumab induction whilst keeping the mobilisation strategy constant. None have compared two mobilisation agents against each other in both daratumumab-exposed and daratumumab-naïve patients.\n\nMethods: We reviewed 66 patients (22 received Ara-C, 44 received CY) who were mobilised at a single centre in Poland between 2018 and 2024. No patients received plerixafor.\n\nResults: Patients who were mobilised with Ara-C collected more CD34+ cells than those who received CY, with a median of 12.6 (IQR 9.1–15.9) versus 7.7 (4.9–12.1) ×10⁶/kg (p=0.005), with comparable apheresis sessions. Previous D-VTd treatment did not reduce the overall yield (p=0.43). The benefit of Ara-C persisted in the D-VTd subgroup, despite heavy confounding between induction and mobilisation choice.\n\nDiscussion: This is the first direct comparison of Ara-C and CY in the daratumumab era. Ara-C-based mobilisation was associated with higher CD34+ yields than CY in a plerixafor-free setting. The apparent advantage in D-VTd-treated patients is exploratory and requires prospective confirmation.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center , ,"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Wojciech Szlasa"
    },
    {
      "affs": [
        0
      ],
      "name": "Artur Borkowski"
    },
    {
      "affs": [
        0
      ],
      "name": "Monika Mordak-Domagała"
    },
    {
      "affs": [
        0
      ],
      "name": "Jacek Kwiatkowski"
    },
    {
      "affs": [
        0
      ],
      "name": "Katarzyna Malesa"
    },
    {
      "affs": [
        0
      ],
      "name": "Mateusz Sawicki"
    },
    {
      "affs": [
        0
      ],
      "name": "Jarosław Dybko"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/74sffz0sy7nzy.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1915658",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690519/?tool=EBI",
  "id": "74sffz0sy7nzy",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13690519",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2720|Multiple Myeloma Research and Treatments"
    ]
  ],
  "openalex": "W7221108361",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690519/pdf/?tool=EBI",
  "pmcid": "PMC13690519",
  "pmid": null,
  "published": "2026-10-09",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/74sffz0sy7nzy.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:59Z",
      "native_id": "PMC:PMC13690519",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13690519"
    },
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1915658",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1915658/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Cytarabine-based mobilisation yields higher CD34+ cell counts than cyclophosphamide regardless of prior daratumumab exposure in multiple myeloma",
  "title_text": "Cytarabine-based mobilisation yields higher CD34+ cell counts than cyclophosphamide regardless of prior daratumumab exposure in multiple myeloma",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:13Z",
  "url": "https://research.draconitic.com/paper/74sffz0sy7nzy",
  "venue": "Frontiers in oncology",
  "versions": []
}